RxDoctor Payments Data

Ehtesham Ghani, MD

Internal Medicine · Brookfield, ILNPI 1316988397

Payments from drug & device makers

$3,729in general payments, 2019–2025

Across 182 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$922
  • Lilly USA, LLC$543
  • Boehringer Ingelheim$436
  • Novo Nordisk$373
  • Johnson & Johnson$260
  • Pfizer$244
  • plus $951 from 15 others

What the payments were for

  • Food & beverage$3,729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,729 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$86,841
Medicare patients
108
Services billed
6,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$53,254
OzempicSemaglutide27$43,015
JanuviaSitagliptin Phosphate25$26,612
JardianceEmpagliflozin21$19,135
EntrestoSacubitril/Valsartan11$7,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,884
Spiriva HandihalerTiotropium Bromide12$5,975
Febuxostat36$3,403
Levothyroxine Sodium114$1,767
Eplerenone12$1,711
Pantoprazole Sodium98$937
Metoprolol Succinate64$932
Albuterol Sulfate HfaAlbuterol Sulfate19$871
Atorvastatin Calcium79$664
Tamsulosin Hcl43$585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$244$53,25466 claims
Novo NordiskOzempic$373$43,01527 claims
Boehringer IngelheimJardiance$436$19,13521 claims
NovartisEntresto$17$7,37511 claims
GSKTrelegy Ellipta$64$6,88411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Brookfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →